Convergence‚ Divergence and Institutional Influence in International HRM Michael Morley Professor of Management University of Limerick 1 Outline of Presentation • A (Short) Personal Perspective on The Financial Crisis • Theoretical and Empirical Challenges in International HRM • Different Lenses in Retrospect: The Meaning of International‚ Comparative and Cross Cultural HRM • Globalisation‚ Convergence & Divergence 2 The Financial Crisis Well we are definitely in a recession…. but what
Premium Multinational corporation
SUPPLY CHAIN SECTOR REPORT ON PHARMACEUTICAL INDUSTRY SRI SRI UNIVERSITY FACULTY OF MANAGEMENT STUDIES (2012-2014) SUBMITTED BY: Shyam Mohankar Priyansh Saxena Mrunalini Negi SUBMITTED TO: Dr.R.K .Padhy Contents 1.0 INTRODUCTION ....................................................................................................................................... 2 PHARMACEUTICAL SUPPLY CHAIN FLOW DIAGRAM .......................................................................
Premium Pharmaceutical industry Pharmacology Clinical trial
1. Introduction ........................................................................................................2 2. The stance of Pfizer ............................................................................................3 2.1 Theories of corporate social responsibility and ethics ...................................3 2.2 Pfizer ’s stance on CSR and ethics ..................................................................4 Bribery of Big Pharma ’s ....................
Premium Business ethics Corporate social responsibility Social responsibility
the way to gain the top spot as the market share leader. Warner-Lambert developed the drug initially but needed to catch up in the market so they teamed up with Pfizer‚ known for their marketing and sales competency. This partnership was just what the doctor ordered for the initial introduction of Lipitor to the market. In 2001‚ Pfizer took full control of Lipitor and changed the marketing game once again. The strategic marketing efforts created competitive advantage for the drug by “delivering
Premium Clinical trial Marketing Pharmaceutical industry
globalization takes place within these Central European countries as according to Matsson 2003‚ the globalization involves changes in the distribution process of goods and services in local markets. Hungary‚ being relatively responsive to open markets and FDI has seen relatively faster reconstruction and development of its logistics system when compared to other eastern countries and its prospects of being a global logistics hub rests contingent on its continued international integration. TABLE OF CONTENTS
Premium Eastern Europe Central Europe Western Europe
Strategy "We aim to gain leadership positions in key growing therapeutic areas and focus on delivering patient-centric‚ innovative therapies. We seek strong‚ long-term relationships that fit our goals and offer a shared vision “ * Company Background: Pfizer is a research-based global pharmaceutical company. The company discovers‚ develops‚ manufactures and markets medicines for humans and animals‚ as well as consumer products. In order To maximize new opportunities in biomedical research‚ and bring more
Premium Pharmaceutical industry Generic drug
Introduction II. About Lipitor (Atorvastatin) III. Pfizer’s strategy IV. Patients seem to benefit from Pfizer’s new strategy V. Potentially profitable for retailers VI. Pfizer after Lipitor VII. Is Pfizer’s Lipitor strategy working? VIII. Wholesaler Profits: Brand vs. Generic drug IX. Pfizer is hoping to sell Lipitor to consumers over the counter (OTC) X. Discussion XI. References Introduction Lipitor (Atorvastatin)‚ the best-selling
Premium Generic drug Food and Drug Administration Pharmaceutical industry
known as acid-test ratio‚ calculates a company’s cash and accounts receivable divided by its current liabilities. This ratio is a more stringent measure of liquidity than the current ratio in that it excludes inventories and other current assets. Pfizer has a quick ratio of 1.78 while the industry median is 1.21. This shows the company does not rely too much on inventory of other assets to pay for short-term liabilities. The current ratio measures a company’s current assets divided by its current
Premium Asset Balance sheet Generally Accepted Accounting Principles
Neurontin was ineffective and went forward. IV. Through my speech you will learn about Pfizer‚ who committed drug fraud and had to pay hefty fines. A. First‚ I will explain who Pfizer is and what the drug Neurontin does. B. Second‚ I will explain what they have done. C. Finally‚ I will discuss the outcome for Pfizer. Body I. I will explain who Pfizer is and what the drug Neurontin does. A. Pfizer is a pharmaceutical company that is dedicated to discovering and developing new and
Premium Epilepsy
Phyllis Hebert and Sierra Harkness FIN571 February 23‚ 2015 William Stokes Cost of Capital In the Wiley plus simulation (2012)‚ we are introduced to Pfizer‚ the world ’s largest research-based pharmaceutical company‚ Pfizer develops their own pharmaceutical products. Ahmed Singh‚ a consultant accountant who works for the Pfizer Treasury Department‚ explains that his role in the company is "to think and plan ahead for what should be the optimal plan structure for the company" (Wiley Plus
Premium Finance Investment Pharmacology